Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Accutar Biotechnology Inc. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners, ensuring a diverse range of perspectives across the pending applications. The prosecution spans 4 distinct art units, which indicates that the company's biotechnological research is categorized into several specialized technical groups at the patent office.
The busiest examiner, HUTTER, GILLIAN A, is handling 1 pending office action. Since each of the 5 pending office actions is managed by a different examiner, no single individual has a disproportionate impact on the portfolio. Practitioners should note that the ratio of 5 distinct examiners to 4 distinct art units suggests that most examiners are working within their own specific technical units. This distribution requires a flexible prosecution strategy that can adapt to the unique requirements of 5 different examiners across multiple specialized fields.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| SANDERSON, LEE E | 1 | 45.2% | +45.2% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263656 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18476063 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707106 | NOVEL SPIROCYCLIC COMPOUNDS AS KLHDC2 LIGANDS | HUTTER, GILLIAN A | — |
| 18404740 | CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | SANDERSON, LEE E | — |
| 18476063 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | SEITZ, ANTHONY JOSEPH | — |
| 18263656 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 3991 | 2 |
| 1625 | 1 |
| 1629 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707106 | NOVEL SPIROCYCLIC COMPOUNDS AS KLHDC2 LIGANDS | HUTTER, GILLIAN A | 1625 | §103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18591704 | CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | KOSACK, JOSEPH R | 3991 | Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18404740 | CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | SANDERSON, LEE E | 3991 | DP | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18476063 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | SEITZ, ANTHONY JOSEPH | 1629 | §101§102 | Final Rejection | — | Pending | Sep 27, 2023 |
| 18263656 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | WILLIS, DOUGLAS M | 1624 | §112Other | Non-Final OA | — | Pending | Jul 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAccutar Biotechnology Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Gillian A Hutter has the most, with 1 of Accutar Biotechnology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
